|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0169 USD | +0.93% |
|
-.--% | +3.68% |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.3M 3.76M 3.47M 3.2M 6.03M 414M 41.45M 16.3M 203M 16.15M 15.8M 698M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.24M 5.45M 5.03M 4.64M 8.74M 601M 60.11M 23.64M 294M 23.42M 22.91M 1.01B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +0.93% | ||
| 3 months | +275.56% | ||
| 6 months | +275.56% | ||
| Current year | +3.68% |
| Current year | 0 | 0.02 | |
| 1 year | 0 | 0.05 | |
| 3 years | 0 | 0.06 | |
| 5 years | 0 | 0.1 | |
| 10 years | 0 | 0.28 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.93% | -.--% | - | - | 4.3M | ||
| +1.23% | +1.82% | +15.61% | +78.24% | 48.15B | ||
| -0.23% | -1.65% | +67.15% | +109.36% | 35.59B | ||
| +1.61% | +1.04% | -2.19% | +36.44% | 11.9B | ||
| +0.46% | +1.56% | +18.45% | +86.06% | 11.85B | ||
| +1.02% | +2.87% | +34.92% | +137.61% | 9.31B | ||
| +3.37% | -0.10% | +51.64% | -4.77% | 7.02B | ||
| +0.58% | +1.18% | +17.12% | +35.97% | 6.91B | ||
| -.--% | +0.14% | - | - | 6.79B | ||
| +0.18% | -2.69% | +2.50% | +202.37% | 6.55B | ||
| Average | +0.91% | -0.61% | +25.65% | +85.16% | 16.01B | |
| Weighted average by Cap. | +0.79% | -0.68% | +30.28% | +86.94% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.55M 3.11M 2.87M 2.64M 4.98M 342M 34.26M 13.48M 168M 13.35M 13.06M 577M | 1.19M 831K 726K 670K 618K 1.16M 80.02M 8.01M 3.15M 39.19M 3.12M 3.05M 135M |
| Net income | -5.8M -4.05M -3.54M -3.27M -3.01M -5.67M -390M -39.04M -15.35M -191M -15.21M -14.88M -658M | -5.94M -4.15M -3.63M -3.35M -3.09M -5.82M -400M -40.01M -15.74M -196M -15.59M -15.25M -674M |
| Net Debt | 759K 530K 463K 427K 394K 743K 51.04M 5.11M 2.01M 25M 1.99M 1.95M 86.05M | 2.77M 1.94M 1.69M 1.56M 1.44M 2.71M 186M 18.66M 7.34M 91.29M 7.27M 7.11M 314M |
Employees
43
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
- ARUXF Stock
Select your edition
All financial news and data tailored to specific country editions
















